Comparison · NCT01829295-sae
Methotrexate vs Mycophenolate Mofetil: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Methotrexate vs Mycophenolate Mofetil: serious adverse events. Trial comparisons, record NCT01829295-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01829295-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0654 | 0.032 | 0.129 | wilson | |
| Risk in group 2 | 0.0642 | 0.0315 | 0.127 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0012 | -0.0696 | 0.0727 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.37 | 2.81 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.345 | 3.01 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Methotrexate than on Mycophenolate Mofetil | 833 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Methotrexate | oral methotrexate~Patients randomized to receive oral methotrexate in Phase I, 0-6 Months.~Methotrexate: For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)~Prednisone: All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study. | 7 | 107 | EG000 |
| Group 2 | Mycophenolate Mofetil | oral mycophenolate mofetil~Patients randomized to receive oral mycophenolate mofetil in Phase I, 0-6 Months.~Mycophenolate mofetil: For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.~Prednisone: All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study. | 7 | 109 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected through the primary endpoint (the first 6 months) for each enrolled patient; Phase I, 0-6 Months.
Source ClinicalTrials.gov
Trial
- Title
- Methotrexate and Mycophenolate Mofetil for UVEITIS
- NCT number
- NCT01829295
- Phases
- PHASE3
- Conditions
- Uveitis
- Interventions
- Mycophenolate mofetil, Methotrexate, Prednisone
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2019-04-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01829295?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01829295-sae